Discontinuation report DAKLINZA
Report ID | 62566 |
Drug Identification Number | 02444755 |
Brand name | DAKLINZA |
Common or Proper name | daclatasvir dihydrochloride) |
Company Name | BRISTOL-MYERS SQUIBB CANADA |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | Daclatasvir |
Strength(s) | 60MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 1 Bottle X 28 |
ATC code | J05AP |
ATC description | |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2019-11-30 |
Actual discontinuation date | |
Remaining supply date | 2019-11-30 |
Discontinuation status | To be discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | Stock will be available until Nov. 30th, 2019 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2344 BOUL. ALFRED-NOBEL, SUITE 300 ST-LAURENT, QUEBEC CANADA H4S 0A4 |
Company contact information | For more information please contact the Customer Service Desk at 1-800-267-0005 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2018-09-28 | French | Compare |
v1 | 2018-09-28 | English | Compare |
Showing 1 to 2 of 2